We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in Intensive Care Unit (ICU) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01734525
Recruitment Status : Unknown
Verified November 2012 by Marcio Nucci, Federal University of Rio de Janeiro.
Recruitment status was:  Recruiting
First Posted : November 27, 2012
Last Update Posted : November 27, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:

This is a prospective study aimed at testing a strategy of early initiation of an antifungal agent to patients admitted to intensive care units (ICUs) at risk for invasive candidiasis. Score system have been developed to identify groups at very high risk for the development of candidemia/invasive candidiasis in the ICU. These scoring system have used clinical information with or without data on Candida colonization, and have shown reasonable correlation with candidemia/invasive candidiasis. More recently, a biomarker - detection of 1,3-beta-D-glucan in the serum - has been tested in the early diagnosis of candidiasis. The incorporation of biomarkers such as beta-D-glucan could help clinicians to select a group at higher risk for candidemia, and despite the fact that these tests may give false-positive results, their negative predictive value could be of great help. Likewise, analyzing the kinetics of these biomarkers in patients with candidemia/invasive candidiasis would help to define their usefulness in monitoring treatment.

Therefore, the objectives of this study are:

  1. To assess the frequency of positive biomarkers in ICU patients at high risk to develop invasive candidiasis/candidemia;
  2. To evaluate the kinetics of positive biomarkers after initiation of antifungal therapy in patients with candidemia;
  3. To test the strategy of early discontinuation of antifungal therapy based on repeatedly negative blood cultures and 1,3 beta-D-glucan in the serum.

Condition or disease Intervention/treatment Phase
Candidemia Drug: Anidulafungin Phase 4

Detailed Description:

Entry criteria are: In the ICU for >2 days AND systemic antibiotics >2 days OR central venous catheter for >days AND at least two of the following: total parenteral nutrition, dialysis, surgery, pancreatitis, receipt of corticosteroids, receipt of other immunosuppressive agents. In addition, patients must have a clinical sign of infection (either one of the following): fever, hypothermia, hypotension, unexplanied acidosis, or unexplained elevation in C-reactive protein.

Eligible patients will be enrolled after signing an informed consent and will have blood obtained for culture and determination of 1,3 beta-D-glucan serum levels for 3 days, and will start anidulafungin IV.

If all tests are negative, anidulafungin will be discontinued on day 4. If 1,3 beta-D-glucan is positive (>80 pg/ml) and / or blood cultures are positive for Candida species, anidulafungin will be continued for >14 days. Blood will oe collected for determination of 1,3 beta-D-glucan on days 7, 10, 14, 17, 21, 24 and 28.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Biomarkers in Invasive Candidiasis in Intensive Care Unit (ICU) Patients
Study Start Date : November 2012
Estimated Primary Completion Date : August 2013
Estimated Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Yeast Infections
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: One arm
Patients at risk will receive therapy with anidulafungin
Drug: Anidulafungin
Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards

Outcome Measures

Primary Outcome Measures :
  1. Exploratory analysis of the kinetics of 1,3 beta-D-glucan in hig-risk patients [ Time Frame: 30 days ]
    The main interst is to evaluate the kinetics of 1,3 beta-D-glucan in hig-risk patients receiving anidulafungin.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • In the ICU for >2 days AND

    • Systemic antibiotics on days 1-3 of ICU OR
    • Central venous catheter on days 1-3 of ICU
  • AND at least 2 of:

    • Total parenteral nutrition on days 1-3 of ICU
    • Any dialysis on days 1-3 of ICU
    • Major surgery in the 7 days before admission in the ICU
    • Pancreatitis in the 7 days before admission in the ICU
    • Use of corticosteroids for at least 3 days in the 7 days before admission
    • Use of other immunosuppressive agents in the 7 days before admission in the ICU
  • In addition, the patient must have at least one of the following:

    • Fever (axillary temperature >37.5 oC)
    • Hypothermia (axillary temperature <35 oC)
    • Hypotension
    • Unexplained acidosis
    • Unexplained elevation in C-reactive protein

Exclusion Criteria:

  • Antifungal for >3 days
  • Allergy to an echinocandin
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01734525

Federal University of Rio de Janeiro Recruiting
Rio de Janeiro, RJ, Brazil, 21941913
Contact: Marcio Nucci, MD    5521-25622463    mnucci@hucff.ufrj.br   
Sub-Investigator: Simone A Nouer, MD         
Sponsors and Collaborators
Universidade Federal do Rio de Janeiro
Study Chair: Marcio Nucci, MD Universidade Federal do Rio de Janeiro
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Marcio Nucci, MD, Federal University of Rio de Janeiro
ClinicalTrials.gov Identifier: NCT01734525     History of Changes
Other Study ID Numbers: Early Therapy
First Posted: November 27, 2012    Key Record Dates
Last Update Posted: November 27, 2012
Last Verified: November 2012

Keywords provided by Marcio Nucci, Federal University of Rio de Janeiro:
intensive care unit
1,3 beta-D-glucan

Additional relevant MeSH terms:
Candidiasis, Invasive
Invasive Fungal Infections
Systemic Inflammatory Response Syndrome
Pathologic Processes
Antifungal Agents
Anti-Infective Agents